Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03106298 · ClinicalTrials.gov registry record
Iron Deficiency and FGF23 Regulation in CKD and HF
A clinical trial of Chronic Kidney Diseases and Iron Deficiency Anemia, sponsored by Northwestern University.
- Completed
- Registry status
- 77
- Enrollment target
- 1
- Study location
NCT03106298 is a study of Chronic Kidney Diseases and Iron Deficiency Anemia that has completed, run by Northwestern University. The registered enrollment target is 77 participants, below the 444-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03106298, a study of Chronic Kidney Diseases and Iron Deficiency Anemia, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- 77 participants
- Enrollment target
- 1
- Study location
Study Summary
This study investigates the effects of intravenous (IV) iron sucrose therapy on blood levels of Fibroblast Growth Factor 23 (FGF23, a protein that regulates the amount of phosphate in the body) in iron deficiency anemia in healthy participants, participants with Congestive Heart Failure (CHF, where the heart does not pump adequate blood supply to the body), participants with Chronic Kidney Disease (CKD, where the kidney function is reduced), and participants with CKD and CHF.
Conditions Studied
Interventions
- DRUG Iron Sucrose
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2015-12-18 |
| Est. Completion | 2018-08-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03106298
The ClinicalTrials.gov registry entry for NCT03106298 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 444-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (83% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Chronic Kidney Diseases appearing as the primary indexed condition, and to 1 intervention - of which Iron Sucrose is the first listed.
NCT03106298 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT03106298 about?
NCT03106298 is a clinical study titled "Iron Deficiency and FGF23 Regulation in CKD and HF". This study investigates the effects of intravenous (IV) iron sucrose therapy on blood levels of Fibroblast Growth Factor 23 (FGF23, a protein that regulates the amount of phosphate in the body) in iron deficiency anemia in healthy participants, participants with Congestive Heart Failure (CHF, where ...
What is the current status of trial NCT03106298?
This trial is currently completed. The enrollment target is 77 participants. The study started on 2015-12-18. Estimated completion is 2018-08-01.
What conditions does trial NCT03106298 study?
This clinical trial studies the following conditions: Chronic Kidney Diseases, Iron Deficiency Anemia, Chronic Heart Failure.
What interventions are being tested in trial NCT03106298?
The interventions under investigation include: Iron Sucrose (DRUG).
Who is sponsoring clinical trial NCT03106298?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03106298 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
RECRUITING
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
-
Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine
RECRUITING · Phase 2
-
Mindfulness in Chronic Kidney Disease
RECRUITING · NA
-
Ferric Citrate and Chronic Kidney Disease in Children
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.